This nationwide cohort study reveals that certain antibiotics, higher-dose steroids, and proton pump inhibitors are associated with reduced overall survival in advanced NSCLC patients receiving first-line pembrolizumab, underscoring the importance of careful comedication monitoring during immunotherapy.